Stockwatch: The commercial paradox of Ebola
This article was originally published in Scrip
There are two factors that limit the ability of the Ebola virus to become a global public health tragedy: its inefficient method of transmission between humans; and its natural reservoir, which seems to be bats located in distal east Africa. These and other facets of the disease paradoxically make the Ebola virus a positive public relations opportunity for big pharmaceutical companies, but a loss-making opportunity for their small biotechnology brethren.
You may also be interested in...
Biogen’s poor third-quarter results cannot be blamed solely on the pandemic. Pipeline attrition and underperformance in most franchises pushes all the risk onto a dubious throw of the regulatory dice.
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.